Mesoblast (ADR) (MESO)
Develops FDA-approved Ryoncil for pediatric steroid-refractory acute graft-versus-host disease.
Something off on this page? Send us feedback.
Develops donor-derived, off-the-shelf cell medicines. Ryoncil is FDA-approved for pediatric steroid-refractory acute graft-versus-host disease, supporting U.S. commercialization.
Develops allogeneic, donor-derived cell medicines designed for off-the-shelf use. Ryoncil, its remestemcel-L-rknd therapy, is FDA-approved for steroid-refractory acute graft-versus-host disease in patients aged two months and older.
Commercialization is centered in the United States after Ryoncil became commercially available. The Melbourne-founded company remains dual-listed in Australia and the United States, with operations spanning the United States, Australia, and Singapore.
Uses well-characterized cell populations and translational studies to design trials against international regulatory criteria. Clinical development, manufacturing, and commercialization also rely on strategic relationships.
Cell-therapy operations are shaped by FDA requirements.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 27, 2026 | Piper Sandler | Reiterate | Rating: —Target: $11 | Target: $39 |
| Nov 25, 2025 | Jefferies | Upgrade | ||
| Jul 18, 2025 | Jefferies | Downgrade | ||
| Dec 23, 2024 | Jefferies | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $102.9M · Total debt $127.3M · Total assets $773.1M · Shareholders' equity $568.4M
- Revenue
- $35.0M
- Operating income
- −$20.5M
- Net income
- −$8.7M
No dividends on record.
| Institutions | 2.98% | 3.87M ADS | |
|---|---|---|---|
| 78 holders · as of Jun 30, 2026 | |||
| Insiders | 34.35% | 44.54M ADS | |
| 9 holders · as of Apr 29, 2026 | |||
| Other | 62.67% | 81.27M ADS | |
| remainder | |||
129.69M ADS (1 ADS = 10 ordinary shares) as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Gregory George1Insiderdirector, 10 percent owner | 22.90% | 288.52M ordinary | filed Apr 13, 2026 |
Silviu ItescuInsiderdirector, officer: CEO and Managing Director | 5.90% | 76.58M ordinary | filed Apr 1, 2026 |
Gueck William J.Insider | 4.98% | 6.45M | filed Sep 16, 2025 |
Morgan StanleyInstitution | 0.55% | 718,608 ADS | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 0.51% | 664,280 ADS | as of Jun 30, 2026 |
- Gregory George's transaction reports restate only vehicles that traded; the 2026 ownership statement (28.85M) plus the 845.6K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Apr 9, 2026 | Gregory George | director, 10 percent owner: | +2,131,890 | $4.93 |
| Apr 10, 2026 | Gregory George | director, 10 percent owner: | +2,324,072 | $1.48 |
| Apr 4, 2026 | Gregory George | director, 10 percent owner: | +4,000,000 | $1.42 |
- Incyte
Direct systemic option in steroid-refractory acute GVHD from age 12
- BioCardia
Clinical-stage cell therapy for ischemic HFrEF
- Sanofi (ADR)
Systemic chronic-GVHD treatment after two prior therapy lines
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Mesoblast (ADR) | $15.30 | −3.89% | $2.06B | — | — | 17.1 | +391.8% |
| Incyte | $124.11 | −2.22% | $25.73B | 16.2 | 51.4 | 4.4 | +37.7% |
| BioCardia | $1.05 | −0.00% | $15.6M | — | — | — | — |
| Sanofi (ADR) | $41.45 | −2.51% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Median | 46.1 | 51.4 | 3.1 | +24.5% |